Biomarker Insights

Scope & Guideline

Exploring innovative pathways in biomarker discovery.

Introduction

Welcome to your portal for understanding Biomarker Insights, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1177-2719
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryNew Zealand
TypeJournal
Convergefrom 2008 to 2024
AbbreviationBIOMARK INSIGHTS / Biomark. Insights
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Biomarker Insights focuses on advancing the understanding and application of biomarkers in various fields of medicine and biology. The journal emphasizes the integration of innovative techniques and multi-omics approaches to enhance biomarker discovery and validation.
  1. Biomarker Discovery and Validation:
    The journal prioritizes research that identifies and validates novel biomarkers for early diagnosis, prognosis, and treatment monitoring across various diseases, particularly cancers and inflammatory conditions.
  2. Multi-Omics Approaches:
    It promotes studies utilizing multi-omics techniques (genomics, proteomics, metabolomics) to provide comprehensive insights into disease mechanisms and biomarker development.
  3. Clinical Applications of Biomarkers:
    The focus extends to the practical application of biomarkers in clinical settings, including their role in personalized medicine, pharmacogenomics, and patient stratification.
  4. Inflammation and Disease:
    A consistent theme involves exploring the relationship between biomarkers and inflammatory processes, addressing their implications in chronic diseases and acute conditions.
  5. Ethnic and Population Studies:
    Research examining the genetic and environmental influences on biomarker expression across different populations, contributing to a more nuanced understanding of disease susceptibility and treatment efficacy.
Biomarker Insights has identified several emerging trends and themes that reflect the evolving landscape of biomarker research, driven by technological advancements and the demand for personalized medicine.
  1. Liquid Biopsy Techniques:
    There is a growing emphasis on liquid biopsy methods for cancer detection and monitoring, reflecting advancements in non-invasive diagnostic strategies that utilize circulating tumor DNA and other biomarkers.
  2. Integration of AI and Machine Learning:
    The incorporation of artificial intelligence and machine learning in biomarker analysis is on the rise, enhancing the ability to interpret complex datasets and identify novel biomarker patterns.
  3. Personalized Medicine and Pharmacogenomics:
    A significant trend involves the application of biomarkers in tailoring individualized treatment plans, particularly in oncology, where genetic profiling informs therapeutic decisions.
  4. Impact of Environmental Exposures:
    Research exploring the effects of environmental factors on biomarker expression, particularly in relation to diseases like cancer and respiratory conditions, is gaining traction.
  5. COVID-19 Related Biomarker Studies:
    The pandemic has catalyzed research into biomarkers associated with COVID-19, particularly in understanding disease severity and long-term effects, which continues to be a significant area of interest.

Declining or Waning

While Biomarker Insights continues to thrive in various research areas, certain themes have shown a decline in prominence over recent years, indicating a potential shift in focus or saturation in the field.
  1. Traditional Biomarker Studies:
    There appears to be a waning interest in conventional biomarker studies that do not incorporate advanced technologies or multi-omics approaches, as the field moves towards more integrative and high-throughput methodologies.
  2. Generalized Inflammation Markers:
    Research focusing on broadly defined inflammatory markers without specific context or application has decreased, suggesting a shift towards more targeted investigations that explore precise inflammatory pathways.
  3. Single Biomarker Studies:
    The trend is moving away from studies that investigate the diagnostic or prognostic value of single biomarkers, as researchers increasingly recognize the complexity of diseases and the need for multi-biomarker panels.

Similar Journals

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Connecting Experts for Groundbreaking Discoveries
Publisher: TAYLOR & FRANCIS ASISSN: 1473-7159Frequency: 12 issues/year

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

International Journal of Clinical and Experimental Pathology

Unlocking the Secrets of Pathology for All
Publisher: E-CENTURY PUBLISHING CORPISSN: 1936-2625Frequency: 12 issues/year

International Journal of Clinical and Experimental Pathology, published by E-CENTURY PUBLISHING CORP, serves as a vital resource for professionals in the field of pathology. With its ISSN 1936-2625, the journal has positioned itself within the competitive landscape of medical journals, achieving commendable rankings in Scopus, particularly in the categories of Pathology and Forensic Medicine (Rank #98/185) and Histology (Rank #38/58). Although its coverage in Scopus has been discontinued, the journal’s past contributions from 2009 to 2017 continue to be a touchstone for researchers interested in advancing their understanding of clinical and experimental pathology. The open-access format ensures accessibility to a wide audience, fostering collaboration and education in this essential medical discipline. By bridging clinical research and experimental findings, this journal plays a crucial role in disseminating knowledge and enhancing practices within pathology, making it an indispensable tool for researchers, professionals, and students alike.

Bioanalysis

Empowering researchers with cutting-edge insights.
Publisher: TAYLOR & FRANCIS LTDISSN: 1757-6180Frequency: 24 issues/year

Bioanalysis is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of analytical and clinical biochemistry. Established in 2009, this journal has become a pivotal platform for high-quality, peer-reviewed research that explores innovative techniques in bioanalytical sciences, appealing to researchers, professionals, and students alike. With an impressive impact factor and ranked in the Q2 and Q3 quartiles across various categories, including Clinical Biochemistry and Pharmacology, Toxicology and Pharmaceutics, Bioanalysis serves as an essential resource for the latest developments in the interdisciplinary aspects of medicine and laboratory technology. While it does not currently offer open access, the journal is indexed in Scopus, ensuring visibility and accessibility to a global audience. The publication's commitment to enhancing knowledge in this vital area of research underscores its significance in fostering advancements that can lead to improved healthcare outcomes.

Byulleten Sibirskoy Meditsiny

Unlocking Insights in Molecular Biology and Therapeutics
Publisher: SIBERIAN STATE MEDICAL UNIVISSN: 1682-0363Frequency: 6 issues/year

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

Clinical Proteomics

Innovative Insights into Protein Dynamics and Health
Publisher: BMCISSN: 1542-6416Frequency: 1 issue/year

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

JOURNAL OF MOLECULAR DIAGNOSTICS

Transforming clinical practice with groundbreaking research.
Publisher: ELSEVIER SCIENCE INCISSN: 1525-1578Frequency: 12 issues/year

The Journal of Molecular Diagnostics is a premier publication in the fields of molecular medicine and pathology, published by Elsevier Science Inc. With an impressive impact factor and recognized as a Q1 journal in both Molecular Medicine and Pathology and Forensic Medicine, this journal is dedicated to advancing the understanding and application of molecular diagnostics in clinical practice. The journal features rigorous peer-reviewed research, comprehensive reviews, and cutting-edge methodologies that highlight novel diagnostic tests and biomarkers. Researchers, professionals, and students in the biomedical sciences are invited to explore its diverse array of articles and contribute to a growing body of knowledge critical for innovation in healthcare delivery. Located in the Netherlands, the journal has secure its position among the top-tier journals with its recent Scopus ranking of 20th out of 208 in Medicine Pathology and Forensic Medicine, reflecting a strong percentile ranking of 90th. With coverage spanning from 1999 to 2024, the Journal of Molecular Diagnostics remains a vital resource for anyone committed to the future of molecular research and diagnostics.

EBioMedicine

Elevating scientific collaboration in the life sciences.
Publisher: ELSEVIERISSN: 2352-3964Frequency: 12 issues/year

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

Biomarkers in Medicine

Elevating Standards in Medical Research and Practice
Publisher: FUTURE MEDICINE LTDISSN: 1752-0363Frequency: 24 issues/year

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

CYTOKINE & GROWTH FACTOR REVIEWS

Advancing the Frontiers of Cytokine and Growth Factor Research
Publisher: ELSEVIER SCI LTDISSN: 1359-6101Frequency: 6 issues/year

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.

Proteomics Clinical Applications

Exploring Proteomics for Enhanced Clinical Applications
Publisher: WILEY-V C H VERLAG GMBHISSN: 1862-8346Frequency: 6 issues/year

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.